This site is intended for U.S. healthcare professionals only.

Compatibility & Incompatibility

Compatibility

KENGREAL® (cangrelor) should be administered via a dedicated IV line.1

Physical compatibility studies using a simulated Y-site have been conducted with KENGREAL®, diluted in 0.9% sodium chloride and commonly used IV products, including those likely for coadministration during PCI. The following products were physically compatible after four hours.1,2

Drug
Concentration
Amiodarone HCL
4 mg/mL
Bivalirudin
5 mg/mL
Diltiazem HCL
5 mg/mL*
Dobutamine HCL
4 mg/mL
Dopamine HCL
4 mg/mL
Fentanyl citrate
12.5 mcg/mL
Heparin sodium
100 units/mL
Metoprolol tartrate
1 mg/mL*
Morphine sulfate
1 mg/mL
Nitroglycerin
0.4 mg/mL
Norepinephrine bitartrate
0.12 mg/mL
Verapamil HCL
1.25 mg/mL
2.5 mg/mL*
Y-site connector

Incompatibility

Compatibility studies have been conducted with commonly used IV products, including those likely for coadministration during PCI. Although the list below is not comprehensive, the following products should NOT be used with KENGREAL® in either an IV line or via a Y-site.

Alteplase
Gentamicin sulfate
Amphotericin B (colloidal)
Labetalol
Butorphanol tartrate
Midazolam
Calcium gluconate
Mycophenolate mofetil
Chlorpromazine
Prochlorperazine edisylate
Ciprofloxacin
Promethazine
Diazepam
Quinupristin/dalfopristin
Diphenhydramine
Reteplase
Droperidol
Tobramycin sulfate

*Tested undiluted (not diluted in 0.9% sodium chloride or 5% dextrose injection).

HCL=hydrochloride; mcg=microgram; mg=milligram; mL=milliliter

References: 1. KENGREAL® (cangrelor) Prescribing Information. 2016. 2. Data on file, Chiesi USA, Inc.

Important Safety Information

KENGREAL® (cangrelor) for Injection is contraindicated in patients with significant active bleeding.

KENGREAL® is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product.

Drugs that inhibit platelet P2Y12 function, including KENGREAL®, increase the risk of bleeding. In CHAMPION PHOENIX, bleeding events of all severities were more common with KENGREAL® than with clopidogrel. Bleeding complications with KENGREAL® were consistent across a variety of clinically important subgroups. Once KENGREAL® is discontinued, there is no antiplatelet effect after an hour.

The most common adverse reaction is bleeding.

Please see full prescribing information.

www.kengreal.com

This site is intended for U.S. healthcare professionals. If you are a U.S. healthcare professional, click OK to continue.

Cancel
Ok